Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Geron Corporation - Common Stock
(NQ:
GERN
)
1.134
+0.014 (+1.24%)
Streaming Delayed Price
Updated: 10:40 AM EST, Nov 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Geron Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
December 13, 2024
From
Geron Corporation
Via
Business Wire
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
December 10, 2024
From
Geron Corporation
Via
Business Wire
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
December 10, 2024
From
Geron Corporation
Via
Business Wire
Analyst Scoreboard: 4 Ratings For Geron
↗
December 10, 2024
Via
Benzinga
Analyst Ratings For Geron
↗
November 05, 2024
Via
Benzinga
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
November 27, 2024
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 21, 2024
From
Geron Corporation
Via
Business Wire
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
November 11, 2024
From
Geron Corporation
Via
Business Wire
Geron to Participate in the Stifel 2024 Healthcare Conference
November 11, 2024
From
Geron Corporation
Via
Business Wire
Geron (GERN) Q3 2024 Earnings Call Transcript
↗
November 07, 2024
GERN earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
November 07, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
November 07, 2024
From
Geron Corporation
Via
Business Wire
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 07, 2024
From
Geron Corporation
Via
Business Wire
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies
November 05, 2024
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 17, 2024
From
Geron Corporation
Via
Business Wire
Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
October 15, 2024
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 19, 2024
From
Geron Corporation
Via
Business Wire
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
September 09, 2024
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 22, 2024
From
Geron Corporation
Via
Business Wire
Geron (GERN) Q2 2024 Earnings Call Transcript
↗
August 08, 2024
GERN earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
September 03, 2024
Via
Benzinga
GERN Stock Earnings: Geron Meets EPS, Beats Revenue for Q2 2024
↗
August 08, 2024
GERN stock results show that Geron met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights
August 08, 2024
From
Geron Corporation
Via
Business Wire
Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
July 26, 2024
From
Geron
Via
Business Wire
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
July 24, 2024
Via
Benzinga
Tesla Posts Weak Earnings, Joins Visa, Deutsche Bank And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
July 24, 2024
Via
Benzinga
Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024
July 23, 2024
From
Geron Corporation
Via
Business Wire
Biotech Bull Market Is Intact But SMIDs Are Too Volatile
↗
July 22, 2024
It was another wild week for the market as it had to contend with a lot of news.
Via
Talk Markets
Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
July 18, 2024
From
Geron Corporation
Via
Business Wire
3 Under-$10 Biotech Stocks That Could Make You Rich
↗
July 11, 2024
Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today